Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | NPY4R | P50391 | 10/20 | 0.44 |
| ▸ | NPY1R | P25929 | 8/20 | 0.44 |
| ▸ | NPY2R | P49146 | 7/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | IL1RN | P18510 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759435 | 0.90 | ERAP2 (0.53) | ERAP2LNPEPERAP1OPRM1OPRD1 | |
| SCHEMBL30759400 | 0.86 | SLC7A5 (0.40) | ERAP2LNPEPERAP1OPRM1OPRD1 | |
| SCHEMBL30759471 | 0.86 | KISS1R (0.42) | ERAP2LNPEPERAP1OPRM1OPRD1 | |
| SCHEMBL30759487 | 0.81 | ERAP2 (0.67) | ERAP2LNPEPERAP1OPRM1OPRD1 | |
| SCHEMBL31754287 | 0.81 | LNPEP (0.45) | ERAP2LNPEPERAP1OPRM1OPRD1 | |
| SCHEMBL30759453 | 0.80 | SLC7A5 (0.42) | ERAP2LNPEPOPRD1 | |
| SCHEMBL29468059 | 0.76 | MME (0.60) | ERAP2LNPEPERAP1OPRM1OPRD1 | |
| SCHEMBL31754252 | 0.76 | KISS1R (0.45) | ERAP2LNPEPERAP1OPRM1OPRD1 | |
| SCHEMBL30759348 | 0.73 | SLC1A2 (0.36) | — | |
| SCHEMBL32661261 | 0.72 | OPRD1 (0.55) | OPRM1OPRD1MMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | ERAP2 3495/4885LNPEP 967/4885ERAP1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.